跳至主要内容
临床试验/NCT00245674
NCT00245674已完成4 期

Solian Solution to Treat Schizophrenic Patients During an Acute Episode

Sanofi1 个研究点 分布在 1 个国家目标入组 300 人开始时间: 2005年6月1日最近更新:
适应症
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
Sanofi
入组人数
300
试验地点
1
主要终点
*analyze the antipsychotic efficacy of amisulpride solution in the first days of an acute schizophrenic episode.

研究概览

简要总结

During this study the efficacy and safety profile will be evaluated of the use of amisulpride in the form of a solution in schizophrenic patients with an acute episode.

The main purpose of the study is to observe the anti-psychotic effect of amisulpride as a solution during the first days of an acute episode of schizophrenia.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • schizophrenic in-patients with an acute episode
  • aged between 18 and 65 years
  • written informed consent

排除标准

  • pregnancy and breast-feeding
  • breast cancer, prolactinoma, pheochromocytoma
  • hypersensitivity to amisulpride or one of the other excipients
  • contra-indications when using amisulpride as per the SmPC

结局指标

主要结局

*analyze the antipsychotic efficacy of amisulpride solution in the first days of an acute schizophrenic episode.

次要结局

  • *analyse the safety profile of amisulpride solution in treatment of schizophrenics with an an acute episode.

研究者

发起方
Sanofi
申办方类型
Industry

研究点 (1)

Loading locations...

相似试验

SOLIACS: Solian Solution in the Acute Setting | 临床试验